These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16722926)

  • 1. Observer variation in immunohistochemical analysis of protein expression, time for a change?
    Kirkegaard T; Edwards J; Tovey S; McGlynn LM; Krishna SN; Mukherjee R; Tam L; Munro AF; Dunne B; Bartlett JM
    Histopathology; 2006 Jun; 48(7):787-94. PubMed ID: 16722926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative immunohistochemistry using the CAS 200/486 image analysis system in invasive breast carcinoma: a reproducibility study.
    Makkink-Nombrado SV; Baak JP; Schuurmans L; Theeuwes JW; van der Aa T
    Anal Cell Pathol; 1995 Apr; 8(3):227-45. PubMed ID: 7547496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitation and morphometric analysis of tumors by image analysis.
    Aziz DC; Barathur RB
    J Cell Biochem Suppl; 1994; 19():120-5. PubMed ID: 7823583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
    Moeder CB; Giltnane JM; Harigopal M; Molinaro A; Robinson A; Gelmon K; Huntsman D; Camp RL; Rimm DL; ;
    J Clin Oncol; 2007 Dec; 25(34):5418-25. PubMed ID: 18048824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study.
    Lacroix-Triki M; Mathoulin-Pelissier S; Ghnassia JP; Macgrogan G; Vincent-Salomon A; Brouste V; Mathieu MC; Roger P; Bibeau F; Jacquemier J; Penault-Llorca F; Arnould L
    Eur J Cancer; 2006 Nov; 42(17):2946-53. PubMed ID: 16989997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis.
    Hameed O; Adams AL; Baker AC; Balmer NE; Bell WC; Burford HN; Chhieng DC; Jhala NC; Klein MJ; Winokur T
    Am J Clin Pathol; 2008 Sep; 130(3):425-7. PubMed ID: 18701416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers.
    Das K; Lorena PD; Ng LK; Shen L; Lim D; Siow WY; Narasimhan K; Teh M; Choolani M; Putti TC; Salto-Tellez M
    Pathology; 2010; 42(6):540-6. PubMed ID: 20854072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray.
    Parker RL; Huntsman DG; Lesack DW; Cupples JB; Grant DR; Akbari M; Gilks CB
    Am J Clin Pathol; 2002 May; 117(5):723-8. PubMed ID: 12090420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications.
    Vörös A; Csörgő E; Nyári T; Cserni G
    Pathobiology; 2013; 80(3):111-8. PubMed ID: 23258384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer.
    Sharangpani GM; Joshi AS; Porter K; Deshpande AS; Keyhani S; Naik GA; Gholap AS; Barsky SH
    J Microsc; 2007 Jun; 226(Pt 3):244-55. PubMed ID: 17535263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
    Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
    Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
    Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue microarray validation: a methodologic study with special reference to lung cancer.
    Karlsson C; Bodin L; Piehl-Aulin K; Karlsson MG
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2014-21. PubMed ID: 19531681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial.
    Mengel M; von Wasielewski R; Wiese B; Rüdiger T; Müller-Hermelink HK; Kreipe H
    J Pathol; 2002 Nov; 198(3):292-9. PubMed ID: 12375261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
    Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A
    Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.